ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Cost Analysis of Radioactive Versus Arthroscopic Synovectomy in Haemophilia: A Brazilian Modelling Approach.
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost Analysis of Radioactive Versus Arthroscopic Synovectomy in Haemophilia: A Brazilian Modelling Approach.Haemophilia : the official journal of the World Federation of HemophiliaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionRadioactive synovectomy (RSO) is an alternative to arthroscopic synovectomy (AR), for treating synovitis. RSO reduces the number of hemarthroses, being less invasive and less costly.
objectiveTo analyse the costs of RSO compared to AR in the treatment of patients with haemophilia in Brazil, using real-world data (RSO) and modelling (AR). METHODOLOGY: We reviewed data from patients with haemophilic synovitis who underwent RSO in two centres in Brazil, from 2003 to 2019. Data of RSO came from actual patients, while those of AR were estimated. We analysed the expenditures for clotting factor concentrates (CFC), hospital stays, and postoperative care. Cost savings of RSO were based on the frequency of hemarthroses 6 months pre and post procedure. The radioisotopes used were Yttrium90 and Samarium153. The Pettersson score was used to assess the severity of haemophilic arthropathy.
resultsThe study included 750 patients who underwent RSO in knees (N = 349), ankles (N = 190), and elbows (N = 211). The median age of patients was 12 years. For RSO in knees, the costs were nearly USD 6000, while AR costs were USD 49,000. The overall costs with CFC for knee hemarthroses decreased from USD 43,506.94 to USD 6,018.64/patient/semester post-RSO. Similar savings were seen with the ankle and elbow.
conclusionRSO offers a clinically effective and economically advantageous alternative compared to AR, for haemophilic synovitis. Integrating RSO into treatment protocols can reduce healthcare costs and improve patient outcomes. Further work is needed, to confirm these findings in other countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.